Hamps Bio IPO - Day 3 Subscription at 228.02 Times

The final day of Hamps Bio's initial public offering showed extraordinary investor enthusiasm, achieving a remarkable overall subscription of 228.02 times by 10:15 AM on December 17, 2024. This exceptional response demonstrates overwhelming market confidence in the company's pharmaceutical and FMCG business model, particularly notable for an SME listing.

Hamps Bio IPO subscription pattern reveals particularly strong retail investor conviction, with this segment reaching an impressive 392.62 times subscription. This extraordinary retail participation suggests strong faith in the company's diverse product portfolio spanning pharmaceuticals and freeze-dried products. The Non-Institutional Investors have also shown robust confidence with 63.33 times subscription, indicating significant interest from wealthy investors in the company's growth prospects.
 

The progression over three days shows consistently building momentum, reflecting growing market recognition of the company's established presence across multiple distribution channels and its strategic positioning in both pharmaceutical and FMCG segments.

Subscription Status of Hamps Bio IPO:

*As of 10:15 AM

Here are the subscription details for Hamps Bio IPO as of Day 3 (17th December 2024, 10:15 AM):

Key Highlights:

• Overall subscription soared to 228.02 times, reflecting exceptional investor confidence
• Retail investors showed overwhelming interest with 392.62 times subscription, worth ₹1,159.37 crores
• NII category demonstrated strong conviction at 63.33 times, worth ₹187.01 crores
• Total bids received for 26.40 crore shares worth ₹1,346.64 crores
• Applications reached 1,93,892, showing widespread retail participation
• Final day response indicated extraordinary market enthusiasm
• Strong momentum maintained across both investor categories
• Subscription pattern suggested robust belief in company's dual-segment strategy

Hamps Bio IPO - Day 2 Subscription at 195.90 Times

Key Highlights:

• Overall subscription reached 195.90 times, building strong momentum
• Retail investors demonstrated growing confidence with 341.61 times subscription
• NII category showed significant improvement at 50.12 times
• Day two response indicated building market enthusiasm
• Strong momentum across investor categories
• Subscription trend suggested robust investor appetite
• Significant improvement from day one levels
• Pattern indicated growing market confidence

Hamps Bio IPO - Day 1 Subscription at 10.61 Times

Key Highlights:

• Overall subscription began impressively at 10.61 times
• Retail investors showed early confidence with 18.87 times subscription
• NII category demonstrated good start with 2.35 times
• Opening day response reflected positive market sentiment
• Strong initial participation indicated brand recognition
• First-day momentum suggested promising investor interest
• Early subscription levels indicated market confidence
• Strong foundation established for subsequent days

About Hamps Bio Limited: 

Incorporated in 2007, Hamps Bio Limited has established itself as a diversified player in pharmaceutical marketing and distribution, offering a comprehensive range of products including tablets, syrups, capsules, and nutritional supplements. The company operates through two distinct segments: pharmaceuticals under the "Hamps" brand and freeze-dried/frozen products under the "FzyEzy" brand.

With a network spanning over 50 distributors and presence on major e-commerce platforms including Amazon (US, Canada, EU), Flipkart, and Jio Mart, the company has demonstrated strong market reach. Their pharmaceutical products are distributed across 8 states and union territories, while their freeze-dried and frozen products reach 6 countries and 22 states and territories. With 78 employees as of October 2024, the company has shown solid financial performance, achieving 16.41% revenue growth and 39.47% PAT increase between FY2023 and FY2024.

Highlights of the Hamps Bio IPO:

• IPO type: Fixed Price Issue
• IPO size: ₹6.22 crores
• Fresh Issue: 12.20 lakh shares
• Face value: ₹10 per share
• Issue price: ₹51 per share
• Lot size: 2,000 shares
• Minimum investment for retail investors: ₹1,02,000
• Minimum investment for HNI: ₹2,04,000 (2 lots)
• Listing at: BSE SME
• IPO opens: December 13, 2024
• IPO closes: December 17, 2024
• Allotment date: December 18, 2024
• Refund initiation: December 19, 2024
• Credit of shares: December 19, 2024
• Listing date: December 20, 2024
• Lead Manager: Marwadi Chandarana Intermediaries Brokers Pvt. Ltd.
• Registrar: Bigshare Services Pvt Ltd
• Market Maker: Pure Broking Private Limited